Dapsone-induced erythroderma with Beau's lines.
A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported. Sudden onset of erythroderma gave rise to a temporary arrest of the function of nail matrix with the resultant Beau's lines. She rapidly recovered with omission of dapsone and therapy with systemic corticosteroids and a topical emollient. In view of the potentially fatal hypersensitivity reaction, we suggest that any patient on multidrug therapy for leprosy needs an urgent referral to a dermatologist if the patient develops a skin rash during the first two months of treatment.
Patki
A H
AH
Mehta
J M
JM
D000328:Adult; D003622:Dapsone / Q000009:adverse effects*; D003873:Dermatitis, Exfoliative / Q000139:chemically induced*; D005260:Female; D006801:Humans; D015440:Leprosy, Lepromatous / Q000188:drug therapy; D009264:Nails, Malformed / Q000139:chemically induced*
D003622:Dapsone